Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry

Christian H. Heeger; Christian M. Tiemeyer; Huong Lan Phan; Roza Meyer-Saraei; Thomas Fink; Vanessa Sciacca; Spyridon Liosis; Ben Brüggemann; Niels Große; Bezhad Fahimi; Samuel Reincke; Karl Heinz Kuck; Feifan Ouyang; Julia Vogler; Charlotte Eitel; Roland R. Tilz

doi:10.1016/j.ijcha.2020.100576

Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry

Christian H. Heeger^*, Christian M. Tiemeyer, Huong Lan Phan, Roza Meyer-Saraei, Thomas Fink, Vanessa Sciacca, Spyridon Liosis, Ben Brüggemann, Niels Große, Bezhad Fahimi, Samuel Reincke, Karl Heinz Kuck, Feifan Ouyang, Julia Vogler, Charlotte Eitel, Roland R. Tilz

^*Corresponding author for this work

Clinic of Internal Medicine II - Cardiology

31 Citations (Scopus)

Abstract

Background: Balloon-based ablation systems for pulmonary vein isolation (PVI) are providing procedural safety and efficacy as well as favourable clinical outcome. Although second-generation laser balloon (LB2) based PVI has been shown safety and efficacy relatively long procedural duration was a strong limitation. The third-generation laser balloon (LB3) offers and automized ablation for rapid PVI. We determined safety, efficacy and procedural characteristics of this new promising ablation system. Methods and results: A total of 15 consecutive patients were prospectively enrolled. All patients underwent PVI using the LB3. A total 59/59 PVs (100%) were successfully isolated. Procedural data was compared to the last 15 consecutive patients treated by the LB2. The median procedure time significantly declined from LB2 (91 (86, 105) min) to LB3 (77 (68, 87) min), p < 0.001. Similarly, the median left atrial dwelling time significantly decreased from LB2 (72 (62, 84) min) to LB3 (45 (38, 52) min), p < 0.0001. The total laser time decreased from LB2 (1920 (1765, 2193) sec) to LB3 (1077 (896, 1165) sec), p < 0.00001. A pure single shot PVI was performed in 18/59 PVs (31%). For major adverse events no differences were detected between the groups (LB2 1/15 (6.7%) and LB3 1/15 (6.7%), p = 0.999). Conclusion: The LB3 was safe and effective for PVI. Procedure time, LA dwelling time and total laser time significantly decreased compared to LB2.

Original language	English
Article number	100576
Journal	IJC Heart and Vasculature
Volume	29
ISSN	2352-9067
DOIs	https://doi.org/10.1016/j.ijcha.2020.100576
Publication status	Published - 08.2020

Funding

CHH received travel grants and research grants by Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus and Speaker’s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. All other authors have no relevant disclosures. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker's honoraria from Medtronic. CHH received travel grants and research grants by Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus and Speaker’s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. All other authors have no relevant disclosures. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker's honoraria from Medtronic.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ijcha.2020.100576

Cite this

Heeger, C. H., Tiemeyer, C. M., Phan, H. L., Meyer-Saraei, R., Fink, T., Sciacca, V., Liosis, S., Brüggemann, B., Große, N., Fahimi, B., Reincke, S., Kuck, K. H., Ouyang, F., Vogler, J., Eitel, C., & Tilz, R. R. (2020). Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry. IJC Heart and Vasculature, 29, Article 100576. https://doi.org/10.1016/j.ijcha.2020.100576

@article{5425922090364af58d3e8417492c8e31,

title = "Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry",

abstract = "Background: Balloon-based ablation systems for pulmonary vein isolation (PVI) are providing procedural safety and efficacy as well as favourable clinical outcome. Although second-generation laser balloon (LB2) based PVI has been shown safety and efficacy relatively long procedural duration was a strong limitation. The third-generation laser balloon (LB3) offers and automized ablation for rapid PVI. We determined safety, efficacy and procedural characteristics of this new promising ablation system. Methods and results: A total of 15 consecutive patients were prospectively enrolled. All patients underwent PVI using the LB3. A total 59/59 PVs (100\%) were successfully isolated. Procedural data was compared to the last 15 consecutive patients treated by the LB2. The median procedure time significantly declined from LB2 (91 (86, 105) min) to LB3 (77 (68, 87) min), p < 0.001. Similarly, the median left atrial dwelling time significantly decreased from LB2 (72 (62, 84) min) to LB3 (45 (38, 52) min), p < 0.0001. The total laser time decreased from LB2 (1920 (1765, 2193) sec) to LB3 (1077 (896, 1165) sec), p < 0.00001. A pure single shot PVI was performed in 18/59 PVs (31\%). For major adverse events no differences were detected between the groups (LB2 1/15 (6.7\%) and LB3 1/15 (6.7\%), p = 0.999). Conclusion: The LB3 was safe and effective for PVI. Procedure time, LA dwelling time and total laser time significantly decreased compared to LB2.",

author = "Heeger, \{Christian H.\} and Tiemeyer, \{Christian M.\} and Phan, \{Huong Lan\} and Roza Meyer-Saraei and Thomas Fink and Vanessa Sciacca and Spyridon Liosis and Ben Br{\"u}ggemann and Niels Gro{\ss}e and Bezhad Fahimi and Samuel Reincke and Kuck, \{Karl Heinz\} and Feifan Ouyang and Julia Vogler and Charlotte Eitel and Tilz, \{Roland R.\}",

note = "Funding Information: CHH received travel grants and research grants by Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus and Speaker{\textquoteright}s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker{\textquoteright}s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. All other authors have no relevant disclosures. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker's honoraria from Medtronic. Funding Information: CHH received travel grants and research grants by Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus and Speaker{\textquoteright}s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker{\textquoteright}s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. All other authors have no relevant disclosures. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker's honoraria from Medtronic. Publisher Copyright: {\textcopyright} 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = aug,

doi = "10.1016/j.ijcha.2020.100576",

language = "English",

volume = "29",

journal = "IJC Heart and Vasculature",

issn = "2352-9067",

}

Heeger, CH, Tiemeyer, CM, Phan, HL, Meyer-Saraei, R, Fink, T, Sciacca, V, Liosis, S, Brüggemann, B, Große, N, Fahimi, B, Reincke, S, Kuck, KH, Ouyang, F, Vogler, J, Eitel, C & Tilz, RR 2020, 'Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry', IJC Heart and Vasculature, vol. 29, 100576. https://doi.org/10.1016/j.ijcha.2020.100576

TY - JOUR

T1 - Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry

AU - Heeger, Christian H.

AU - Tiemeyer, Christian M.

AU - Phan, Huong Lan

AU - Meyer-Saraei, Roza

AU - Fink, Thomas

AU - Sciacca, Vanessa

AU - Liosis, Spyridon

AU - Brüggemann, Ben

AU - Große, Niels

AU - Fahimi, Bezhad

AU - Reincke, Samuel

AU - Kuck, Karl Heinz

AU - Ouyang, Feifan

AU - Vogler, Julia

AU - Eitel, Charlotte

AU - Tilz, Roland R.

N1 - Funding Information: CHH received travel grants and research grants by Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus and Speaker’s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. All other authors have no relevant disclosures. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker's honoraria from Medtronic. Funding Information: CHH received travel grants and research grants by Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus and Speaker’s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. RRT received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, SentreHeart and Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, Sano Aventis and research grants by Cardiofocus. CE received travel grants and educational grants by Medtronic. All other authors have no relevant disclosures. KHK received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received speaker's honoraria from Medtronic. Publisher Copyright: © 2020 The Author(s) Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/8

Y1 - 2020/8

N2 - Background: Balloon-based ablation systems for pulmonary vein isolation (PVI) are providing procedural safety and efficacy as well as favourable clinical outcome. Although second-generation laser balloon (LB2) based PVI has been shown safety and efficacy relatively long procedural duration was a strong limitation. The third-generation laser balloon (LB3) offers and automized ablation for rapid PVI. We determined safety, efficacy and procedural characteristics of this new promising ablation system. Methods and results: A total of 15 consecutive patients were prospectively enrolled. All patients underwent PVI using the LB3. A total 59/59 PVs (100%) were successfully isolated. Procedural data was compared to the last 15 consecutive patients treated by the LB2. The median procedure time significantly declined from LB2 (91 (86, 105) min) to LB3 (77 (68, 87) min), p < 0.001. Similarly, the median left atrial dwelling time significantly decreased from LB2 (72 (62, 84) min) to LB3 (45 (38, 52) min), p < 0.0001. The total laser time decreased from LB2 (1920 (1765, 2193) sec) to LB3 (1077 (896, 1165) sec), p < 0.00001. A pure single shot PVI was performed in 18/59 PVs (31%). For major adverse events no differences were detected between the groups (LB2 1/15 (6.7%) and LB3 1/15 (6.7%), p = 0.999). Conclusion: The LB3 was safe and effective for PVI. Procedure time, LA dwelling time and total laser time significantly decreased compared to LB2.

AB - Background: Balloon-based ablation systems for pulmonary vein isolation (PVI) are providing procedural safety and efficacy as well as favourable clinical outcome. Although second-generation laser balloon (LB2) based PVI has been shown safety and efficacy relatively long procedural duration was a strong limitation. The third-generation laser balloon (LB3) offers and automized ablation for rapid PVI. We determined safety, efficacy and procedural characteristics of this new promising ablation system. Methods and results: A total of 15 consecutive patients were prospectively enrolled. All patients underwent PVI using the LB3. A total 59/59 PVs (100%) were successfully isolated. Procedural data was compared to the last 15 consecutive patients treated by the LB2. The median procedure time significantly declined from LB2 (91 (86, 105) min) to LB3 (77 (68, 87) min), p < 0.001. Similarly, the median left atrial dwelling time significantly decreased from LB2 (72 (62, 84) min) to LB3 (45 (38, 52) min), p < 0.0001. The total laser time decreased from LB2 (1920 (1765, 2193) sec) to LB3 (1077 (896, 1165) sec), p < 0.00001. A pure single shot PVI was performed in 18/59 PVs (31%). For major adverse events no differences were detected between the groups (LB2 1/15 (6.7%) and LB3 1/15 (6.7%), p = 0.999). Conclusion: The LB3 was safe and effective for PVI. Procedure time, LA dwelling time and total laser time significantly decreased compared to LB2.

UR - https://www.scopus.com/pages/publications/85087300489

U2 - 10.1016/j.ijcha.2020.100576

DO - 10.1016/j.ijcha.2020.100576

M3 - Journal articles

AN - SCOPUS:85087300489

SN - 2352-9067

VL - 29

JO - IJC Heart and Vasculature

JF - IJC Heart and Vasculature

M1 - 100576

ER -

Rapid pulmonary vein isolation utilizing the third-generation laserballoon – The PhoeniX registry

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this